首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

2037559

生物相似藥市場預測至2034年－按產品類型、給藥途徑、應用、通路和地區分類的全球分析

Biosimilars Market Forecasts to 2034 - Global Analysis By Product Type, Route of Administration, Application, Distribution Channel, and By Geography

出版日期: 2026年05月11日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的預測，全球生物相似藥市場預計將在 2026 年達到 466 億美元，並在預測期內以 15.4% 的複合年成長率成長，到 2034 年達到 1,465 億美元。

生物相似藥是指與已核准的參考生物製藥高度相似的生物藥物，在安全性、純度和療效方面均無臨床意義上的差異。這些生物製藥有效的替代療法正在改變癌症、自體免疫疾病和糖尿病等慢性病和危及生命的疾病的治療方式。市面上的產品種類繁多，均經過嚴格的分析和臨床試驗以證明其生物相似性，這不僅為醫療保健系統節省了大量成本，也為全球患者提供了更多獲得先進生物療法的機會。

生物製藥專利到期和醫療成本上升

眾多重磅生物製藥專利的到期為生物相似藥的研發和商業化創造了巨大的市場機會。Adalimumab、曲妥珠單抗和Rituximab等關鍵生物製藥的專利保護已經或即將到期，這使得製藥公司能夠開發價格更親民的替代藥物，而無需像新藥研發那樣進行大規模臨床試驗。由於人口老化和昂貴的專科治療，世界各地的醫療保健系統面臨前所未有的預算壓力，因此正積極透過優惠的報銷政策和處方獎勵來推廣生物相似藥的使用。這種「專利懸崖」效應和成本控制需求的雙重作用，使得已開發經濟體對生物相似藥的需求持續旺盛，這些經濟體都希望更有效地利用其醫療保健預算。

複雜的製造和監管要求

與小分子學名藥的研發和生產需要更大的投資和更先進的技術。生物製藥的生產涉及活細胞株，需要對無數變數進行精確控制；即使是微小的製程變化也會影響產品的特性、安全性和有效性。雖然生物製藥的監管核准流程比新藥簡單，但仍需要大量的分析數據、非臨床數據和臨床數據來證明其生物相似性。這種複雜性對中小型製造商構成了巨大的進入門檻，迫使他們建造高成本且配備專業品管系統的生產設施。通常長達6至9年的研發週期，不僅會延遲市場進入，還會縮短競爭對手出現之前的商業性優勢期。

將應用拓展到新的治療領域

持續的研究正在拓展生物相似藥的開發領域，使其不再局限於傳統的腫瘤和自體免疫疾病適應症，而是擴展到先前未開發的治療領域。目前，針對需要抗VEGF療法的眼科疾病、以酵素替代療法治療的罕見遺傳性疾病以及現有胰島素製劑無法涵蓋的代謝性疾病，正在研發新的生物相似性。分析技術和生產流程的進步使得在生物相似藥開發中實現以往難以複製的生物製藥結構（例如複雜的融合蛋白）成為可能。治療領域的拓展，加上醫生對生物相似藥在主流臨床實踐中接受度的提高以及臨床經驗的積累，正為生產商創造巨大的成長機遇，促使他們拓展產品線，不再局限於第一代參考產品。

相互溝通的挑戰和醫生的懷疑態度

儘管臨床證據支持生物相似藥的安全性和有效性，但醫生不願開立處方以及藥劑師替代能力的局限性是其市場滲透的主要障礙。獲得「互換性認定」（允許在藥房層面實現無需臨床醫生參與的自動替代）需要進行額外的轉換試驗，而這些試驗是生物類似藥基本核准所需試驗之外的。如果沒有這項認定，處方醫師必須明確核准每張處方，這會阻礙生物相似藥的推廣應用，並維持病患對原廠藥的品牌忠誠度。除了醫生與原廠藥公司之間的牢固關係外，患者對從現有治療方法轉換的擔憂也進一步阻礙了生物相似藥的推廣應用，即使它們在整個醫療保健系統中具有顯著的成本優勢。

新冠疫情的影響：

新冠疫情對生物相似藥的影響錯綜複雜，一方面擾亂了生產，另一方面又加速了推動其應用的相關因素。封鎖措施和臨床試驗中斷導致多種生物相似藥的上市和監管決策延遲，尤其影響需要招募病患的後期研發產品。然而，隨著醫療系統逐漸擺脫疫情帶來的經濟壓力，對成本控制的日益重視加速了生物相似藥的應用，以降低專科藥物的支出。疫情期間遠端保健和強化輸液中心的興起，證明了治療方案轉換管理的可行性，並降低了現有患者轉用替代治療方法的風險認知。這些系統性變化為後疫情時代醫療機構採用生物相似藥創造了更有利的環境。

在預測期內，單株抗體細分市場預計將佔據最大的市場佔有率。

預計在預測期內，單株抗體領域將佔據最大的市場佔有率。這反映了這些生物製藥在全球暢銷藥品中的主導地位。單株抗體可用於治療多種高發生性疾病，包括乳癌、大腸癌、類風濕性關節炎和乾癬。在專利到期前，原廠藥每年的總收入已達數百億美元。大量患者需要接受此類治療，加上原廠藥價格高昂，為生物相似藥競爭者創造了龐大的潛在市場。領先的生物相似藥開發商正優先開發單株抗體，因為其具有巨大的商業性潛力，從而催生了多種核准上市的單株抗體產品，例如Adalimumab、Bevacizumab和Rituximab昔單抗，進一步加速了此類藥物的上市和市場成長。

在預測期內，皮下給藥領域預計將呈現最高的複合年成長率。

在預測期內，皮下給藥領域預計將呈現最高的成長率，這主要得益於患者和醫療服務提供者越來越傾向於選擇自我給藥療法而非靜脈注射。皮下給藥無需前往輸液中心，從而減少了醫療資源的消耗，提高了患者的便利性和生活品質。生物相似藥開發商正日益重視參考產品的皮下製劑，以滿足市場對居家治療方案的需求，同時延長專利保護期。新冠疫情進一步加速了這一趨勢，因為患者和醫療服務提供者都希望盡可能減少就醫次數。先前僅能透過靜脈注射給藥的生物製藥製劑，如今推出了新的皮下製劑，這為生物類似藥的開發創造了全新的機遇，並在整個預測期內顯著擴大了該給藥途徑的目標市場。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其全球最高的生物製藥支出以及完善的生物相似藥監管路徑。美國是全球最大的藥品市場，其在生物製藥上的支出正透過生物相似藥的推廣應用創造顯著的成本節約機會。近期推出的政策舉措，包括生物相似藥創新計畫和相互替代性指南，正在縮短核准時間並加劇市場競爭。領先的生物相似藥生產商在該地區擁有大規模的業務，這有助於其進入市場並開展醫生教育計畫。藥品福利管理機構和醫療保健系統日益重視成本控制，這在公立和私人醫療保健項目中都創造了對生物相似藥替代品的持續需求。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的快速發展、龐大的患者群體以及政府鼓勵生物類似藥推廣的政策。中國、印度、韓國和日本等國已建立高效率的生物相似藥核准監管流程，多家國內生產商也已獲得國際監管認證。由於該地區各國政府的醫療體系面臨著在控制支出的同時擴大治療覆蓋範圍的壓力，生物相似藥已成為一項極具吸引力的政策工具。亞太地區強大的生產能力和低廉的生產成本使其成為全球主要的生物相似藥生產中心和快速成長的終端用戶市場，吸引了大量投資用於研發能力和商業基礎設施建設。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

Amgen Inc
Pfizer Inc
Novartis AG
Biocon Limited
Celltrion Inc
Samsung Bioepis Co Ltd
Teva Pharmaceutical Industries Ltd
Viatris Inc
Dr Reddys Laboratories Ltd
Fresenius Kabi AG
Stada Arzneimittel AG
Sandoz Group AG
Alvotech SA
Coherus BioSciences Inc
Apotex Inc
Lupin Limited

簡介目錄圖表

Product Code: SMRC35974

According to Stratistics MRC, the Global Biosimilars Market is accounted for $46.6 billion in 2026 and is expected to reach $146.5 billion by 2034 growing at a CAGR of 15.4% during the forecast period. Biosimilars are biologic medical products highly similar to already approved reference biologics, with no clinically meaningful differences in safety, purity, or potency. These cost-effective alternatives to expensive biologic therapies are transforming treatment landscapes for chronic and life-threatening conditions including cancer, autoimmune disorders, and diabetes. The market encompasses a diverse range of products developed through rigorous analytical and clinical testing to demonstrate biosimilarity, offering healthcare systems significant cost savings while expanding patient access to advanced biologic treatments across global markets.

Market Dynamics:

Driver:

Expiration of biologic patents and rising healthcare costs

The expiration of patents for numerous blockbuster biologic drugs has opened substantial market opportunities for biosimilar development and commercialization. Major biologics including adalimumab, trastuzumab, and rituximab have lost or are losing patent protection, allowing manufacturers to develop affordable alternatives without the extensive clinical trial requirements of novel drugs. Healthcare systems worldwide, facing unprecedented budget pressures from aging populations and expensive specialty therapies, actively encourage biosimilar adoption through favorable reimbursement policies and prescribing incentives. This convergence of patent cliffs and cost containment imperatives creates sustained demand for biosimilars across developed economies seeking to stretch healthcare budgets further.

Restraint:

Complex manufacturing and regulatory requirements

Developing and producing biosimilars demands significantly greater investment and technical expertise compared to generic small-molecule drugs. Manufacturing biologics involves living cell systems requiring precise control over countless variables, with even minor process changes potentially affecting product characteristics, safety, and efficacy. Regulatory approval pathways, while streamlined compared to novel biologics, still require extensive analytical, non-clinical, and clinical data demonstrating biosimilarity. This complexity creates substantial barriers to entry for smaller manufacturers and necessitates costly manufacturing facilities with specialized quality systems. The extended development timelines, typically six to nine years, delay market entry and reduce the commercial window before subsequent competition arrives.

Opportunity:

Expanding applications into new therapeutic areas

Ongoing research is opening biosimilar development opportunities beyond traditional oncology and autoimmune indications into previously untapped therapeutic categories. Novel biosimilars are being developed for ophthalmologic conditions requiring anti-VEGF therapies, rare genetic disorders treated with enzyme replacement therapies, and metabolic conditions beyond current insulin offerings. Advances in analytical technologies and manufacturing processes are making previously difficult-to-copy biologic structures, including complex fusion proteins, increasingly feasible for biosimilar development. This therapeutic expansion, combined with growing physician acceptance and clinical experience with biosimilars in mainstream practice, creates substantial growth opportunities as manufacturers diversify their pipelines beyond first-generation reference products.

Threat:

Interchangeability challenges and physician skepticism

Despite clinical evidence supporting biosimilar safety and efficacy, physician reluctance to prescribe and pharmacists' limited ability to substitute create significant market penetration barriers. Interchangeability designation, allowing automatic substitution at the pharmacy level without clinician involvement, requires additional switching studies exceeding those required for basic biosimilar approval. Without this designation, biosimilars face adoption friction as prescribers must explicitly authorize each prescription, perpetuating brand loyalty to reference products. Entrenched relationships between physicians and innovator pharmaceutical companies, combined with patient concerns about switching established treatments, further impede uptake even where cost differences substantially favor biosimilar adoption across healthcare systems.

Covid-19 Impact:

The COVID-19 pandemic created a complex impact pattern for biosimilars, simultaneously disrupting manufacturing while accelerating adoption forces. Lockdowns and clinical trial disruptions delayed several biosimilar launches and regulatory decisions, particularly affecting products in late-stage development requiring patient enrollment. However, healthcare systems emerging from pandemic-induced financial strains intensified focus on cost containment, accelerating biosimilar uptake to reduce specialty drug expenditures. The shift toward telehealth and centralized infusion centers during the pandemic demonstrated that managed treatment transitions are feasible, reducing perceived risks of switching established patients. These systemic changes have created a more favorable post-pandemic environment for biosimilar adoption across institutional healthcare settings.

The Monoclonal Antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to account for the largest market share during the forecast period, reflecting these biologics' dominant position among top-selling pharmaceutical products worldwide. Monoclonal antibodies treat numerous high-prevalence conditions including breast cancer, colorectal cancer, rheumatoid arthritis, and psoriasis, with reference products collectively generating tens of billions in annual revenue before patent expirations. The substantial patient populations requiring these therapies, combined with high reference product prices, creates enormous addressable markets for biosimilar competitors. Leading biosimilar developers prioritize monoclonal antibodies due to their commercial potential, resulting in multiple approved products for molecules like adalimumab, bevacizumab, and rituximab, further accelerating adoption and market growth.

The Subcutaneous segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the subcutaneous segment is predicted to witness the highest growth rate, driven by patient and provider preferences for self-administered therapies over intravenous alternatives. Subcutaneous administration eliminates the need for infusion center visits, reducing healthcare resource utilization and improving patient convenience and quality of life. Biosimilar developers increasingly prioritize subcutaneous versions of reference products, extending patent protection while meeting market demand for home-based treatment options. The COVID-19 pandemic further accelerated this trend as patients and providers sought to minimize healthcare facility visits. Emerging subcutaneous formulations for previously intravenous-only biologics are creating entirely new biosimilar opportunities, substantially expanding the addressable market for this administration route throughout the forecast period.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the highest global spending on biologic therapies and established biosimilar regulatory pathways. The United States represents the world's largest pharmaceutical market, with biologic expenditures creating substantial savings opportunities through biosimilar adoption. Recent policy initiatives, including the Biosimilar Innovation Program and Interchangeability Guidance, have accelerated approval timelines and increased competition. Major biosimilar manufacturers maintain significant commercial operations in the region, facilitating market access and physician education programs. The growing influence of pharmacy benefit managers and health systems prioritizing cost containment creates sustained demand for biosimilar alternatives across both private insurance and government healthcare programs.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid healthcare infrastructure development, large patient populations, and government policies promoting biosimilar adoption. Countries including China, India, South Korea, and Japan have established streamlined regulatory pathways for biosimilar approval, with several domestic manufacturers achieving international regulatory certifications. Government healthcare systems across the region face pressure to expand treatment access while controlling expenditures, making biosimilars attractive policy tools. The region's strong manufacturing capabilities and lower production costs position Asia Pacific as both a major production hub for global biosimilars and a rapidly growing end-user market, attracting substantial investment in development capabilities and commercial infrastructure.

Key players in the market

Some of the key players in Biosimilars Market include Amgen Inc, Pfizer Inc, Novartis AG, Biocon Limited, Celltrion Inc, Samsung Bioepis Co Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr Reddys Laboratories Ltd, Fresenius Kabi AG, Stada Arzneimittel AG, Sandoz Group AG, Alvotech SA, Coherus BioSciences Inc, Apotex Inc, and Lupin Limited.

Key Developments:

In April 2026, Biocon announced the U.S. commercial launch of Bosaya(TM) and Aukelso(TM) (denosumab-kyqq), biosimilars to Amgen's Prolia(R) and Xgeva(R). These products were granted interchangeable status by the FDA, following a settlement with Amgen that allowed market entry in late 2025.

In March 2026, Celltrion launched its high-dose (300 mg) Omlyclo(R) (omalizumab) in Korea, a biosimilar to Xolair(R). This followed late 2025 approvals in the U.S. (December) and EU (November).

In October 2025, Amgen completed a Phase 3 study for ABP 206 (nivolumab) comparing pharmacokinetic similarity to the reference product in patients with resected advanced melanoma.

Product Types Covered:

Monoclonal Antibodies
Erythropoietin
Insulin
Human Growth Hormone
Granulocyte-Colony Stimulating Factor
Interferons
Fusion Proteins
Other Product Types

Route of Administrations Covered:

Intravenous
Subcutaneous
Other Route of Administrations

Applications Covered:

Oncology
Autoimmune Diseases
Blood Disorders
Diabetes
Growth Hormone Deficiency
Other Applications

Distribution Channels Covered:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Biosimilars Market, By Product Type

5.1 Monoclonal Antibodies
5.2 Erythropoietin
5.3 Insulin
5.4 Human Growth Hormone
5.5 Granulocyte-Colony Stimulating Factor
5.6 Interferons
5.7 Fusion Proteins
5.8 Other Product Types

6 Global Biosimilars Market, By Route of Administration

6.1 Intravenous
6.2 Subcutaneous
6.3 Other Route of Administrations

7 Global Biosimilars Market, By Application

7.1 Oncology
7.2 Autoimmune Diseases
7.3 Blood Disorders
7.4 Diabetes
7.5 Growth Hormone Deficiency
7.6 Other Applications

8 Global Biosimilars Market, By Distribution Channel

8.1 Hospital Pharmacies
8.2 Retail Pharmacies
8.3 Online Pharmacies
8.4 Specialty Clinics

9 Global Biosimilars Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 Amgen Inc
12.2 Pfizer Inc
12.3 Novartis AG
12.4 Biocon Limited
12.5 Celltrion Inc
12.6 Samsung Bioepis Co Ltd
12.7 Teva Pharmaceutical Industries Ltd
12.8 Viatris Inc
12.9 Dr Reddys Laboratories Ltd
12.10 Fresenius Kabi AG
12.11 Stada Arzneimittel AG
12.12 Sandoz Group AG
12.13 Alvotech SA
12.14 Coherus BioSciences Inc
12.15 Apotex Inc
12.16 Lupin Limited

簡介目錄圖表

List of Tables

Table 1 Global Biosimilars Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Biosimilars Market Outlook, By Product Type (2023-2034) ($MN)
Table 3 Global Biosimilars Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
Table 4 Global Biosimilars Market Outlook, By Erythropoietin (2023-2034) ($MN)
Table 5 Global Biosimilars Market Outlook, By Insulin (2023-2034) ($MN)
Table 6 Global Biosimilars Market Outlook, By Human Growth Hormone (2023-2034) ($MN)
Table 7 Global Biosimilars Market Outlook, By Granulocyte-Colony Stimulating Factor (2023-2034) ($MN)
Table 8 Global Biosimilars Market Outlook, By Interferons (2023-2034) ($MN)
Table 9 Global Biosimilars Market Outlook, By Fusion Proteins (2023-2034) ($MN)
Table 10 Global Biosimilars Market Outlook, By Other Product Types (2023-2034) ($MN)
Table 11 Global Biosimilars Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 12 Global Biosimilars Market Outlook, By Intravenous (2023-2034) ($MN)
Table 13 Global Biosimilars Market Outlook, By Subcutaneous (2023-2034) ($MN)
Table 14 Global Biosimilars Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
Table 15 Global Biosimilars Market Outlook, By Application (2023-2034) ($MN)
Table 16 Global Biosimilars Market Outlook, By Oncology (2023-2034) ($MN)
Table 17 Global Biosimilars Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
Table 18 Global Biosimilars Market Outlook, By Blood Disorders (2023-2034) ($MN)
Table 19 Global Biosimilars Market Outlook, By Diabetes (2023-2034) ($MN)
Table 20 Global Biosimilars Market Outlook, By Growth Hormone Deficiency (2023-2034) ($MN)
Table 21 Global Biosimilars Market Outlook, By Other Applications (2023-2034) ($MN)
Table 22 Global Biosimilars Market Outlook, By Distribution Channel (2023-2034) ($MN)
Table 23 Global Biosimilars Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
Table 24 Global Biosimilars Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
Table 25 Global Biosimilars Market Outlook, By Online Pharmacies (2023-2034) ($MN)
Table 26 Global Biosimilars Market Outlook, By Specialty Clinics (2023-2034) ($MN)